Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)

Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed) is sponsored by National Institute of General Medical Sciences (NIGMS) at NIH. Funding opportunity for technology development research, potentially supporting schistosomiasis-related projects.

Expired PAR-25-202: Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed) This notice has expired. For NIH, in limited situations, applications may be accepted on a case-by-case basis for a short period after expiration to accommodate NIH late or continuous submission policies . Contact the eRA Service Desk for any submission issues.

Check the NIH Guide for active opportunities and notices. Department of Health and Human Services Part 1.

Overview Information Participating Organization(s) National Institutes of Health ( NIH ) Components of Participating Organizations National Institute of General Medical Sciences ( NIGMS ) Funding Opportunity Title Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed) R21 Exploratory/Developmental Research Grant Notices of Special Interest associated with this funding opportunity May 12, 2026 - Notice of Early Expiration of PAR-25-202 "Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)".

See Notice NOT-GM-26-005 . January 28, 2026 - NIH Removing AIDS Application Due Dates from NOFOs. See Notice NOT-OD-26-029 .

March 31, 2025 - This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission. April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025.

See Notice NOT-OD-24-084 . August 31, 2022 - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198 .

August 5, 2022 - Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189 . Funding Opportunity Number (FON) Companion Funding Opportunity See Section III.

3. Additional Information on Eligibility. Assistance Listing Number(s) Funding Opportunity Purpose This Notice of Funding Opportunity (NOFO)supports exploratory research leading to proof of concept for the development of new technologies relevant to the NIGMS mission.

Projects should entail a high degree of risk and/or novelty, and have a high future potential impact in biomedical research.

Outcomes or products of the proposed project, which should significantly advance the current state of the art, may include, but are not limited to: laboratory instruments and other devices, chemical reagents and processes, biological molecules or systems that have been modified by human intervention for use as research tools.

This NOFO does not support technology development that is narrowly focused on addressing specific biological questions or that re-purposes existing technologies for new uses. Rather, applications should propose development of new tools that can potentially benefit a broad spectrum of biomedical research. Moreover, feasibility of the proposed technology must not have already been established in the literature or with preliminary data.

Applications that are focused on technology development to address specific biological questions and/or include unpublished or published data that provide proof of concept are not responsive to this NOFO and will be administratively withdrawn without review.

Funding Opportunity Goal(s) The National Institute of General Medical Sciences (NIGMS) supports basic research that increases our understanding of biological processes and lays the foundation for advances in disease diagnosis, treatment, and prevention.

NIGMS also supports research in specific clinical areas that affect multiple organ systems: anesthesiology and peri-operative pain; clinical pharmacology ​common to multiple drugs and treatments; and injury, critical illness, sepsis, and wound healing. ​ NIGMS-funded scientists investigate how living systems work at a range of levels—from molecules and cells to tissues and organs—in research organisms, humans, and populations.

Additionally, to ensure the vitality and continued productivity of the research enterprise, NIGMS provides leadership in supporting the training of future of scientists, and developing research capacity throughout the country. Open Date (Earliest Submission Date) The following table includes NIH standard due dates marked with an asterisk.

Renewal / Resubmission / Revision (as allowed) AIDS - New/Renewal/Resubmission/Revision, as allowed All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. New Date May 12, 2026 per issuance of NOT-GM-26-005 .

(Original Expiration Date: January 08, 2028 ) Required Application Instructions It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide , except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts ). Conformance to all requirements (both in the Application Guide and the NOFO) is required and strictly enforced.

Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants. gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

Use the NIH ASSIST system to prepare, submit and track your application online. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants. gov and eRA Commons to track your application.

Check with your institutional officials regarding availability. Workspace to prepare and submit your application and eRA Commons to track your application. Part 1.

Overview Information Part 2. Full Text of Announcement Section I. Notice of Funding Opportunity Description Section II.

Award Information Section III. Eligibility Information Section IV. Application and Submission Information Section V.

Application Review Information Section VI. Award Administration Information Section VII. Agency Contacts Section VIII.

Other Information Part 2. Full Text of Announcement Section I. Notice of Funding Opportunity Description Support for Early-Stage Technology Development Is Critical to Advancing Biomedical Research Technological advances are crucial for accelerating biomedical research.

Technology enables science by providing new ways to address questions, and more importantly, by allowing researchers to pose new questions that could not be anticipated in the absence of the enabling technology. New knowledge drives the imperative for new tools, and those tools stimulate new questions, in a mutually reinforcing feedback loop that drives science forward.

Early technology development can be described in two stages: (I) exploratory proof-of-concept research to determine the feasibility and best approach(es) for a technology development project, and (II) the subsequent research and development that focus on creating and validating a working prototype technology before application to untested biomedical problems is possible.

This NOFO invites projects in Stage I - evaluation of an untested concept. A companion NOFO, PAR-25-203 Focused Technology Research and Development (R01- Clinical Trial Not Allowed) supports Stage II projects - i.e., research and development of a working prototype.

Applications that address specific biological questions in addition to developing specific technologies are not responsive to the goals of these NOFOs but may be submitted to the Parent R01 funding announcement or other NOFOs (e.g., NIGMS Maximizing Investigators' Research Awards ).

Applications to this NOFO should propose technology development at a conceptual stage , not yet supported by any proof-of-concept data, in order to demonstrate feasibility of the proposed technology and/or establish the most likely path to successful development.

When compared to current state-of-the-art technology, the proposed concept should lead to a technological breakthrough or a significant tool to advance current biomedical research. The project’s starting point should be the current state of knowledge, and concepts of the new technology must not have been already tested for feasibility.

Project aims should focus on either(a) exploratory research to identify, among several possibilities, the approach with the highest likelihood of success, or (b) demonstrating feasibility of a specific novel approach.

For this NOFO, technology refers to tools, methods, and techniques that enable a broad spectrum of biomedical research that falls within the NIGMS mission including, but not limited to: laboratory instruments and other devices, chemical reagents and processes, biological molecules or systems that have been modified by human intervention for use as research tools.

Further, this NOFO calls for innovative exploratory technology development predicated on an explicitly described broad need or challenge in biomedical research. This need should exceed current technological capability, with the state-of-the-art technological performance defining the starting point.

Comparison of the proposed technical performance improvement to the state of the art will provide the rationale for developing a fundamentally different technology. While specific well-characterized test systems may be used for validation, applications should highlight the broad utility of the technology for biomedical research.

Proof of Concept: This NOFO supports proof-of-concept studies to develop prototypes and exploratory technologies that do not have demonstrated feasibility in the literature, are not based on preliminary data, and are not obvious extensions of the current state of the art. The expected project outcome must be a clear test of concept, either positive or negative.

The proposed concept must be innovative, represent a significant advance over the state of the art, and address current obstacles to advancing biomedical research. Validation: Application to synthetic models or well-characterized biological systems to assess performance can be included at this stage.

To be considered for funding, applications of the technology must be limited to well-characterized models or systems chosen to facilitate technology development rather than to immediately address biological questions. The project aims must be focused entirely on the technology development.

Non-Responsiveness Criteria Biological Questions: Applications that include aims that address specific biological questions are not responsive to the goals of this NOFO and will be administratively withdrawn without review. However, validation of a technology against known, well-characterized standards is encouraged.

Although biomedical relevance is an essential element of NIH research, this stage of technology development should not include immediate short-term application of nascent technologies to challenging biomedical research questions.

Information that establishes feasibility or proof of concept: Applications that include published or unpublished results that support the feasibility of the Specific Aims, forecast the project objectives, develop proof of concept or significantly mitigate risk are not responsive to the goals of the NOFO and will be administratively withdrawn.

Relevance of Research Topics for this NOFO Prospective applicants are strongly advised to consult with the Scientific/Research Contact(s) listed in Part 2. Section VII. Agency Contacts for guidance on assessing the application's relevance for this NOFO.

Final determination of application responsiveness for this NOFO will be based on NIH Staff assessment of the submitted full application. Applications that are determined to be non-responsive to this NOFO, or that propose research topics that are not appropriate for NIGMS, will be administratively withdrawn.

The NIGMS mission is to support basic research that increases our understanding of biological processes and lays the foundation for future advances in disease diagnosis, treatment, and prevention. NIGMS-funded scientists investigate how living systems work at a range of levels - from molecules and cells to tissues and organs - in research organisms, humans, and populations.

The institute’s research mission is aimed at understanding the principles, mechanisms, and processes that underlie living organisms, often using research models. NIGMS also supports the development of fundamental methods and new technologies to achieve its mission. Supported research may utilize specific cells or organ systems if they serve as models for understanding general principles.

research and technology development that is aimed at understanding general principles, mechanisms, and processes through Scientific Divisions with broad interests, research in specific clinical areas that affect multiple organ systems such as anesthesiology and peri-operative pain, sepsis, clinical pharmacology that is common to multiple drugs and treatments, trauma, burn injury, and wound healing.

research focused on single classes of cells, tissues, organs, or diseases unless they are used as models for elucidating basic principles, technology development for a specific disease and/or organ system beyond the specific ones listed above, HIV/AIDS-related applications. Prospective applicants are encouraged to visit NIGMS Technology Development Programs (R21 and R01) for more details.

Note: Applications that propose technology development with the following characteristics will be of low funding priority: incremental advances of technology, obvious substitution of one known element for another, technology that will only lead to an incremental advance in biomedical research, combinations of prior elements with additive utility, technologies that are ready for advanced development and validation. See Section VIII.

Other Information for award authorities and regulations. Section II. Award Information Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.

Application Types Allowed The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO. Not Allowed: Only accepting applications that do not propose clinical trials.

Need help determining whether you are doing a clinical trial? Funds Available and Anticipated Number of Awards The number of awards is contingent upon NIH appropriations and the number of meritorious applications. Application budgets are limited to a total of $275,000 Direct Costs over the two-year project period.

No more than $200,000 Direct Costs may be requested in any single year. Direct cost limits exclude consortium F&A costs. The budget must be well justified and reflect the actual needs of the proposed project.

The maximum project period is 2 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO. Section III.

Eligibility Information Higher Education Institutions Public/State Controlled Institutions of Higher Education Private Institutions of Higher Education Nonprofits Other Than Institutions of Higher Education Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education) Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education) For-Profit Organizations (Other than Small Businesses) City or Township Governments Special District Governments Indian/Native American Tribal Governments (Federally Recognized) Indian/Native American Tribal Governments (Other than Federally Recognized).

Eligible Agencies of the Federal Government U.S. Territory or Possession Independent School Districts Public Housing Authorities/Indian Housing Authorities Native American Tribal Organizations (other than Federally recognized tribal governments) Faith-based or Community-based Organizations Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement , are allowed. Applicant organizations must complete and maintain the following registrations as described in the How to Apply- Application Guide to be eligible to apply for or receive an award.

All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference the NIH Grants Policy Statement Section 2.

3. 9. 2 Electronically Submitted Applications for additional information.

System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually . The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.

NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM. Unique Entity Identifier (UEI) - A UEI is issued as part of the SAM. gov registration process.

The same UEI must be used for all registrations, as well as on the grant application. eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants. gov registrations; all registrations must be in place by time of submission.

eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application. Grants. gov – Applicants must have an active SAM registration in order to complete the Grants.

gov registration. Program Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons.

If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Eligible Individuals (Program Director/Principal Investigator) Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply-Application Guide. This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement Section 1. 2 Definition of Terms .

3. Additional Information on Eligibility Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.

3. 7. 4 Submission of Resubmission Application .

This means that the NIH will not accept: A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application. A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.

An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2. 3. 9.

4 Similar, Essentially Identical, or Identical Applications ). Section IV. Application and Submission Information 1.

Requesting an Application Package The application forms package specific to this opportunity must be accessed through ASSIST, Grants. gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.

gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution. 2.

Content and Form of Application Submission It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced.

Applications that are out of compliance with these instructions may be delayed or not accepted for review. All page limitations described in the How to Apply- Application Guide and the Table of Page Limits must be followed. Instructions for Application Submission The following section supplements the instructions found in the How to Apply- Application Guide and should be used for preparing an application to this NOFO.

All instructions in the How to Apply - Application Guide must be followed. SF424(R&R) Project/Performance Site Locations All instructions in the How to Apply- Application Guide must be followed. SF424(R&R) Other Project Information All instructions in the How to Apply- Application Guide must be followed.

Other Attachments: The application must include the following attachment: Letter from the PD/PI: This signed letter from the PD/PI must confirm adherence to the following responsiveness criteria: The proposed project focuses solely on new technology development, ideas, or concepts; The project does not include biomedical aims or tests of biological hypotheses; The application does not include published or unpublished data that support feasibility of the project aims; The application does not propose re-purposing of existing technologies from other research areas If this letter is not included, the application will be considered incomplete and will not be reviewed.

Applications that include this letter but are found to be nonresponsive by the NIGMS Technology Development NOFO Team will be withdrawn without review. Please name the file "Letter from PD/PI". SF424(R&R) Senior/Key Person Profile All instructions in the How to Apply- Application Guide must be followed.

All instructions in the How to Apply- Application Guide must be followed. All instructions in the How to Apply-Application Guide must be followed. PHS 398 Cover Page Supplement All instructions in the How to Apply- Application Guide must be followed.

All instructions in the How to Apply- Application Guide must be followed, with the following additional instructions: Specific Aims: Applications should propose to advance technical knowledge. Technical advances should be novel, inventive entities or methods that have potential future utility to advance biomedical research.

Examples of supported technologies include, but are not limited to, instruments, devices, algorithms, software, chemicals, biomolecules, cells, or modified organisms that have potential value for enabling new biomedical research. In addition to the topics outlined in the SF424 (R&R) Application Guide, Describe the potential impact of the tool that will be developed and its anticipated utility for biomedical research.

Articulate the potential of the proposed technology to address substantial unmet needs or solve longstanding technical problems in biomedical research. Because this is very early-stage exploratory technology development, impact is not likely to be immediate. Nonetheless, the possible future impact of the proposed technology must be compelling and clearly articulated.

In addition to the topics outlined in the SF424 (R&R) Application Guide, Outline the unique nature of the technical opportunity that will be developed in the project. Describe how the technology concept is a novel, inventive entity or method. Provide limitations of the state of the art and the rationale for developing a fundamentally different technology.

Describe the project innovation by the extent of technical advance over the state of the art or potential advance enabled for biomedical research. In addition to the topics outlined in the SF424 (R&R) Application Guide, Describe those aspects of the experimental approach that are specific to exploratory technology development.

These include the uncertainties underlying the proposed technology research and development, including the risk of failure. Provide the rationale for the approach(es) to be explored in the project. Describe how feasibility or proof of concept for the technology will be established.

Outline how data will be obtained, analyzed, and interpreted with sufficient rigor to quantitatively assess feasibility of the technology. For exploratory research, high risk is expected, and milestones might not be reached on a predictable timetable. Describe the desired performance characteristics of the proposed technology that will be used to evaluate progress toward achieving the project goals.

While inclusion of untested biological questions will not be funded, validation of the nascent technology with well-characterized models or gold standard biological samples is encouraged. Explain the rationale for the selection of validation systems in terms of the desired technology performance and how a validation system will facilitate technology development.

Describe how experimental results from the exploratory project will serve as a foundation for next phase development efforts such as an R01, small business grant, or equivalent. For exploratory research, it is expected that further technical development will be necessary to achieve biomedical research utility. Project objectives should be novel and not obvious compared to the current state of the art.

Therefore, evidence that the concept is achievable would demonstrate positive proof of concept and is not allowed by this NOFO. To ensure that feasibility or proof of concept has not been evaluated, do not include or refer to unpublished and/or preliminary data, results, or conclusions, since these forecast an increased likelihood of success.

Published data for establishing the state of the art can be provided through literature citations, published data from other sources including preprints with a DOI number, or theoretical principles. Any published data that forecast the success of the project objectives or develop proof of concept are not responsive to this NOFO.

Resource Sharing Plan : Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply- Application Guide.

All instructions in the How to Apply-Application Guide must be followed, with the following additional instructions: All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan.

All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan. Appendix: Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the How to Apply- Application Guide.

No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.

PHS Human Subjects and Clinical Trials Information When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply- Application Guide, with the following additional instructions: If you answered “Yes” to the question “Are Human Subjects Involved?

” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record. Study Record: PHS Human Subjects and Clinical Trials Information All instructions in the How to Apply- Application Guide must be followed.

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the How to Apply- Application Guide must be followed. PHS Assignment Request Form All instructions in the How to Apply- Application Guide must be followed.

3. Unique Entity Identifier and System for Award Management (SAM) See Part 2. Section III.

1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants. gov 4. Submission Dates and Times Part I.

contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday , the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants. gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons , NIH’s electronic system for grants administration.

NIH and Grants. gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.

gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Grants Policy Statement Section 2.

3. 9. 2 Electronically Submitted Applications .

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission. Information on the submission process and a definition of on-time submission are provided in the How to Apply-Application Guide. 5.

Intergovernmental Review (E. O. 12372) This initiative is not subject to intergovernmental review.

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement . Pre-award costs are allowable only as described in the NIH Grants Policy Statement Section 7. 9.

1 Selected Items of Cost. 7. Other Submission Requirements and Information Applications must be submitted electronically following the instructions described in the How to Apply Application Guide.

Paper applications will not be accepted. Applicants must complete all required registrations before the application due date. Section III.

Eligibility Information contains information about registration. For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide . If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance.

For assistance with application submission, contact the Application Submission Contacts in Section VII. All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form . Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.

See Section III of this NOFO for information on registration requirements. The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the How to Apply Application Guide.

See more tips for avoiding common errors. Upon receipt, applications will be evaluated for completeness and compliance with application instructions and responsiveness to the NOFO by the Center for Scientific Review and NIGMS. Applications that are incomplete, non-compliant, or non-responsive will not be reviewed.

Applications must include an attachment titled “Letter from PD/PI” as an Other Attachment on the Other Project Information form. Applications that fail to include this attachment will be considered incomplete and will be administratively withdrawn before review.

Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. See Mandatory Disclosures, 2 CFR 200. 113 and NIH Grants Policy Statement Section 4.

1. 35 . Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to the HHS Office of Inspector Grant Self Disclosure Program at [email protected] .

Post Submission Materials Applicants are required to follow the instructions for post-submission materials, as described in the policy Section V. Application Review Information Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

For this particular announcement, note the following: The Exploratory Research for Technology Development program uses the R21